-
-
Overview
-
Carfilzomib is a derivative of the microbially-derived natural product epoxomycin. It irreversibly inhibits the chymotrypsin-like activity of the 20S proteasome with high potency and selectivity at several orders of magnitude over epoxomycin. In 2012, Carfilzomib was approved by the FDA for use in patients with relapsed and refractory multiple myeloma. It is in clinical trials for other cancers as well.
Please contact us at for specific academic pricing.
-
- Properties
-
Overview
- Home
- Products
- Life Science
- Analytical Chromatography
- Antibodies
- Assay Kits
- Antigens
- Biochemical Reagents
- Biospecimens
- Cell Culture
- Cell Analysis
- Chemicals
- Cloning and Expression
- Collagen
- Nucleic Acid Detection
- Nucleic Acid Extraction
- Enzymes
- Glycan Analysis
- Hydrogels
- Immunohistochemistry (IHC)
- Ion Exchange Resins
- Liposomes
- Microbiology
- Nanoparticles
- Nucleic Acid Electrophoresis
- Nucleic Acid Synthesis
- PCR
- Proteins
- Protein Biochemistry
- Protein Gel Electrophoresis
- Transfection Reagents
- Ubiquitin-Proteasome
- Venoms
- Lab Solutions
- Amerigo Scientific Instrument
- 3D Bioprinting
- Medical Devices
- Life Science
- Services
- About Us
- Contact Us
.
